Sivem ezetimibe 10 mg tablets: One lot recalled as some bottles may contain perindopril 4 mg tablets
OTTAWA, ON, May 23, 2025 /CNW/ –
Summary
Product: Sivem ezetimibe 10 mg tablets
Issue: Health products – Product safety
What to do: If your bottle of ezetimibe 10 mg tablets contains any perindopril 4 mg tablets, or if you are unsure, return it to your pharmacy immediately. If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance. Seek immediate medical attention if you are experiencing serious side effects, including symptoms of a severe allergic reaction, such as difficulty breathing or swallowing or severe swelling of the lips, mouth or throat.
Affected products
Product
DIN
Lot number
Expiry date
Sivem ezetimibe 10 mg tablets
02429659
100063638
2026-07-31
Issue
Sivem Pharmaceuticals ULC is recalling one lot of Sivem ezetimibe 10 mg tablets because some bottles may also contain perindopril 4 mg tablets. Taking perindopril when prescribed ezetimibe may pose serious health risks.
Ezetimibe is a prescription drug used by adults and children 10 years of age and older to lower cholesterol and other fats in the blood. Perindopril is a prescription drug used in adults to treat high blood pressure.
Patients not normally prescribed perindopril may experience side effects such as a drop in blood pressure, dizziness, light-headedness or fainting. Other possible effects could include headache, cough, or gastrointestinal discomfort (e.g., nausea, vomiting or diarrhea). The risk can be higher in people with low blood pressure, kidney problems, or those taking other medications that affect blood pressure. Patients unknowingly taking a medication could also have a severe allergic reaction to that medication.
Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to prevent this issue from reoccurring. The Department will inform the public if any new health risks are identified.
What you should do
Check your medication bottle to ensure it only contains Sivem ezetimibe 10 mg tablets.
Sivem ezetimibe 10 mg is a white oblong tablet, with '93' stamped on one side and 'A11' on the other.
Perindopril 4 mg is a spotted light green oblong tablet, with '4' stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges.
If the bottle contains any unusual tablets, or if you are unsure, return it to your pharmacy immediately. Your pharmacist will check the tablets and provide you with a replacement, if needed.
If you are unable to return your tablets to the pharmacy right away, talk to your pharmacist or doctor for further guidance.
Seek immediate medical attention if you are experiencing serious side effects (e.g., dizziness, light-headedness or fainting, or severe allergic reaction).
If you have questions about this recall, contact Sivem Pharmaceuticals by calling 1-855-757-4836 or by emailing drugsafety@mckesson.ca.
Report any health product-related side effects or complaints to Health Canada.
Sivem ezetimibe 10 mg is a white oblong tablet, with '93' stamped on one side and 'A11' on the other.
Perindopril 4 mg is a spotted light green oblong tablet, with '4' stamped on one side and nothing stamped on the other. The tablet is scored (indented) on both middle edges.
Additional information for health professionals:
Health care professionals, such as pharmacists, should check bottles of Sivem ezetimibe 10 mg tablets before dispensing to ensure they do not contain perindopril 4 mg tablets. Report any unusual bottles or other issues to the company and to Health Canada.
Également disponible en français
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
13-06-2025
- Malaysian Reserve
Oracare Baby Brush toothbrush recalled from Dollarama due to a potential choking hazard
OTTAWA, ON, June 13, 2025 /CNW/ – Summary Product: Oracare Baby Brush toothbrush Issue: Health products – Product safety What to do: Immediately stop using the Oracare Baby Brush toothbrush intended for children. Return the product to the store where you purchased it for a refund. Affected products Oracare Baby Brush toothbrush IssueHealth Canada is advising consumers about a recall of the Oracare Baby Brush toothbrush sold at Dollarama stores across Canada. The toothbrush may pose a choking hazard due to a manufacturing defect that can cause it to break into two pieces. Dollarama has received 1 consumer complaint concerning this manufacturing defect; however, there have been no choking incidents reported to the company or Health Canada to date. Dollarama has advised Health Canada that it will no longer import or sell the Oracare Baby Brush toothbrush. The company is advising consumers, especially parents and caregivers of children, to stop using this product and return it to Dollarama for a refund. Health Canada will continue to monitor the situation and will take appropriate and timely action should new information become available. What you should do Stop using the Oracare Baby Brush toothbrush immediately. Seek immediate medical attention from a health care professional if injury has occurred from using Oracare Baby Brush toothbrush. Report any health product-related side effects or complaints to Health Canada. Également disponible en français
Malaysian Reserve
13-06-2025
- Malaysian Reserve
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
VANCOUVER, BC, June 13, 2025 /CNW/ – UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain Grant Awarded: $4,845,000 'This platform represents a critical step toward advancing spinal cord injury research globally,' said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. 'By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients.' 'With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience,' said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. 'By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments.' These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. 'The UBC neuroscience community is grateful for Brain Canada's continued support,' said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. 'These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan.' Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: 'By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives.' These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. 'Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries,' said the Honourable Marjorie Michel, Minister of Health. 'Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes.'
Malaysian Reserve
06-06-2025
- Malaysian Reserve
Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
TORONTO, June 6, 2025 /CNW/ – Sunday, June 8, 2025 — National advocacy organization Obesity Matters will host the Your Health Matters Summit 2025 at the historic Old Mill Toronto, with virtual access available across Canada. This one-day, community-powered event is creating space for real stories, honest conversations, and stigma-free care — putting people, not just conditions, at the center of health and wellness. With the theme 'Inspire Change. Build Connection. Advance Wellness.', the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support. 'Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity,' says Priti Chawla, Executive Director of Obesity Matters.'This summit is about rewriting the narrative — one story, one connection, one person at a time.' Program highlights include: Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience Dr. Megha Poddar on hormone health across life stages Dr. Peter Selby facilitating a storytelling session with patient advocates Dr. David Macklin on Resilience… The Secret Skill to Success A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters. 'We can't let outdated ideals or social media define what health looks like,' says Dr. Sandy Van.'In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind.' 'For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment.' — Sandra Elia, Chair, Obesity Matters For full program details, visit:
